Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEMETREXED DITROMETHAMINE vs PEMFEXY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.
FDA-approved: In combination with cisplatin for initial treatment of patients with malignant pleural mesothelioma who are unresectable or not surgical candidates.,FDA-approved: As a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy.,FDA-approved: In combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC.,Off-label: Treatment of recurrent or metastatic cervical cancer, breast cancer, bladder cancer, colorectal cancer, and others.
Mesothelioma: In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.,Non-small cell lung cancer: First-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with pembrolizumab and platinum chemotherapy.,Non-small cell lung cancer: Maintenance therapy for patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.,Non-small cell lung cancer: Treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.
500 mg/m2 intravenously over 10 minutes every 21 days.
500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
Terminal elimination half-life ~17 hours (range 13-26 hours) in patients with normal renal function; prolonged to >24 hours in renal impairment. Supports every-21-day dosing.
Pemetrexed is primarily excreted unchanged in the urine. It undergoes minimal hepatic metabolism; less than 5% is metabolized by the liver.
Pemetrexed is primarily excreted unchanged in the urine; limited hepatic metabolism occurs via unspecified pathways. It is not significantly metabolized by CYP450 enzymes.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Renal excretion (70-90% unchanged drug), biliary/fecal (<5%)
81% bound primarily to albumin; minimal binding to alpha-1-acid glycoprotein.
~95% bound to plasma proteins (primarily albumin)
Vd at steady state = 16.1 L/m² (approximately 0.4 L/kg in adults). Clinical meaning: Indicates distribution into total body water with limited tissue binding; low Vd suggests minimal extravascular distribution.
Vd ~16 L/m² (approximately 0.4 L/kg); distributes into total body water with extensive tissue binding.
Intravenous only; bioavailability is 100% by IV route. Not orally available due to poor absorption and extensive first-pass metabolism.
IV only; no oral bioavailability due to poor absorption and extensive first-pass metabolism.
Cr Cl ≥45 m L/min: 500 mg/m2; Cr Cl 30-44 m L/min: 375 mg/m2; Cr Cl <30 m L/min: not recommended.
Cr Cl 45-59 m L/min: reduce dose to 400 mg/m2; Cr Cl 30-44 m L/min: reduce dose to 250 mg/m2; Cr Cl <30 m L/min: do not administer.
No dose adjustment recommended for Child-Pugh A or B. Child-Pugh C: no data.
No dosage adjustment required for Child-Pugh class A or B. For Child-Pugh class C, reduce dose by 50%.
Not established; safety and efficacy not determined in pediatric patients.
Safety and efficacy not established in pediatric patients; not recommended.
No specific dose adjustment; monitor renal function closely due to age-related decline in Cr Cl.
No dose adjustment based on age alone; monitor renal function and adjust according to Cr Cl.
Pemetrexed can cause severe or fatal hypersensitivity reactions, including anaphylaxis. It also causes severe myelosuppression, which may require dose modification or discontinuation. Patients must be pretreated with corticosteroids and vitamin supplementation to reduce toxicity.
PEMFEXY can cause fetal harm when administered to a pregnant woman. Pemetrexed is contraindicated in patients who are pregnant or may become pregnant. Women of childbearing potential should be advised to avoid becoming pregnant during treatment with PEMFEXY.
Myelosuppression: Dose-dependent, monitor blood counts regularly.,Renal toxicity: Excreted renally; adjust dose in renal impairment (Cr Cl <45 m L/min).,Gastrointestinal toxicity: Nausea, vomiting, diarrhea; may require antiemetics.,Hypersensitivity reactions: Premedicate with corticosteroids.,Folic acid and vitamin B12 deficiency: Supplement to reduce hematologic toxicity.,Third-space fluid accumulation: Consider drainage before treatment.
Myelosuppression: Pemetrexed can cause severe bone marrow suppression, including neutropenia, thrombocytopenia, and anemia. Monitor blood counts and adjust doses accordingly.,Renal toxicity: Pemetrexed is primarily eliminated renally; reduce dose in patients with creatinine clearance <45 m L/min. Not recommended for patients with Cr Cl <30 m L/min.,Cutaneous reactions: Severe dermatologic reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported; discontinue if severe.,Gastrointestinal toxicity: Diarrhea, nausea, and vomiting are common; administer premedication with corticosteroids and folic acid/vitamin B12 to reduce toxicity.,Pneumonitis: Interstitial pneumonitis has been reported; monitor for respiratory symptoms and discontinue if confirmed.,Radiation recall: Increased risk of radiation recall reactions in patients who have received prior radiotherapy.
History of severe hypersensitivity reaction to pemetrexed or any excipients.,Concurrent yellow fever vaccine (risk of systemic fatal disease).,Severe renal impairment (Cr Cl <45 m L/min) not meeting criteria for dose adjustment.
Pregnancy: Pemetrexed can cause fetal harm; contraindicated in pregnant women.,Severe hypersensitivity: History of severe hypersensitivity reaction to pemetrexed or any excipient.,Concomitant yellow fever vaccine: Increased risk of systemic vaccine reaction.,Breastfeeding: Discontinue nursing during treatment due to potential harm to the infant.
No specific dietary restrictions. However, folic acid supplements and vitamin B12 are required. Avoid folic acid antagonists like methotrexate.
No known food interactions. However, avoid grapefruit juice if taking concurrent CYP3A4 substrates due to potential enzyme inhibition? Not applicable for PEMFEXY. No dietary restrictions required.
Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA synthesis and cell division. First trimester exposure carries the highest risk of major congenital malformations (e.g., neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and potential fetal demise. Use in pregnant women is not recommended unless no safer alternative exists.
Category D: Positive evidence of human fetal risk. Avoid in pregnancy unless no safer alternative. First trimester: high risk of neural tube defects, craniofacial and limb malformations, growth restriction. Second/third trimester: increased risk of preterm delivery, low birth weight, fetal myelosuppression.
There are no data on the presence of pemetrexed in human milk, its effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is not recommended during pemetrexed therapy and for at least one week after the last dose. The M/P ratio is unknown.
Excreted in human milk. M/P ratio unknown. Potential for serious adverse reactions in nursing infants, including myelosuppression. Advise discontinue breastfeeding or the drug, considering importance to mother.
No specific dosing adjustments for pregnancy are established due to lack of data. Physiologic changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce drug exposure, but dose increases are not recommended due to potential fetal toxicity. In animal studies, lower doses produced embryotoxicity. Therefore, dose adjustments should not be made; the drug should be avoided in pregnancy.
Pregnancy-induced increases in plasma volume and renal clearance may decrease pemetrexed exposure. No formal dose recommendations; consider therapeutic drug monitoring if available. Use with folic acid and vitamin B12 supplementation to reduce toxicity.
Administer folic acid and vitamin B12 supplementation to reduce toxicity. Premedicate with corticosteroids to prevent rash. Monitor renal function; dose adjust for Cr Cl <45 m L/min. Avoid NSAIDs for 2 days before and after dose. Ensure adequate hydration. Do not mix with calcium-containing solutions.
PEMFEXY (pembrolizumab) is a humanized monoclonal antibody that targets PD-1. Clinical pearls: 1) Administer as IV infusion over 30 minutes; do not shake vial. 2) Monitor for immune-mediated adverse reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. 3) Corticosteroids may be used to manage severe immune-related adverse events. 4) Do not coadminister with systemic immunosuppressants unless managing toxicity. 5) No dose adjustment required for renal or mild hepatic impairment. 6) Check PD-L1 expression for NSCLC appropriateness.
Take folic acid daily and vitamin B12 injections every 9 weeks as prescribed.,Inform all healthcare providers about your treatment; avoid NSAIDs like ibuprofen or naproxen.,Report new or worsening rash, diarrhea, or mouth sores immediately.,Drink plenty of fluids to stay hydrated.,Avoid receiving live vaccines during treatment.
Inform your healthcare provider about any history of autoimmune disease, organ transplant, or lung problems.,Report new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, blood in stool, jaundice, severe fatigue, weight changes, or skin rash.,Do not receive live vaccines during treatment.,Avoid pregnancy while on treatment; use effective contraception.,Report signs of infusion reaction such as fever, chills, flushing, or hypotension during and after infusion.
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEMETREXED DITROMETHAMINE vs PEMFEXY, answered by our medical review team.
PEMETREXED DITROMETHAMINE is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.. PEMFEXY is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEMETREXED DITROMETHAMINE and PEMFEXY depend on the specific clinical indication. These are both Antineoplastic Antifolate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEMETREXED DITROMETHAMINE is: 500 mg/m2 intravenously over 10 minutes every 21 days.. The standard adult dose of PEMFEXY is: 500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEMETREXED DITROMETHAMINE and PEMFEXY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEMETREXED DITROMETHAMINE is classified as Category C. Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA . PEMFEXY is classified as Category C. Category D: Positive evidence of human fetal risk. Avoid in pregnancy unless no safer alternative. First trimester: high risk of neural tube defects, craniofacial and limb malforma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.